國家衛生研究院 NHRI:Item 3990099045/7946
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 857841      Online Users : 837
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7946


    Title: Characterization of the clinical, biological, and therapeutic relevance of EZH2 overexpression in myxofibrosarcoma
    Authors: Li, CF;Huang, HY
    Contributors: National Institute of Cancer Research
    Abstract: Background: Myxofi brosarcoma is genetically complex and insuffi ciently characterized in molecular determinants of clinical aggressiveness. By reappraising the public transcriptome (GSE21122), EZH2 was identifi ed as a top-ranking differentially upregulated gene among those regulating chromatin organization (GO:0006325) in myxofi brosarcoma tissues.Design: To validate the pathogenetic role of EZH2 in myxofi brosarcoma, mRNA abundance and protein expression of EZH2 were determined in independent samples by branched-chain DNA (bDNA) and immunohistochemical assays, yielding 40 and 87 informative cases, respectively. In vitro, RNA interference and DZNep treatment (targeting EZH2 associated PRC2 complex) were applied in EZH2-expressing myxofi brosarcoma cell lines to evaluate for the biological functions and therapeutic relevance of EZH2. The in vivo effect of DZNep treatment was examined in xenograft models established from two myxofi brosarcoma cell lines.Results: EZH2 protein overexpression was associated with higher histological grade (p=0.002), worse disease-specifi c and metastasis-free survival (both p£0.0001), and mRNA upregulation (p=0.010). In all myxofi brosarcoma cell lines, stable EZH2 knockdown resulted in impaired cell proliferative, migratory, and invasive capabilities with concomitant reductions in anchorage-independent colony formation and well-formed endothelial tubes. In vitro, DZNep caused dose- and time-dependent cytotoxicity and downregulated PRC2-associated proteins with induction of cellular apoptosis and attenuation of EZH2 promoter transactivity. The dose-dependent therapeutic effi cacy of DZNep was further corroborated in vivo in both xenograft myxofi brosarcoma models.Conclusions: EZH2 overexpression plays an oncogenic role in myxofi brosarcoma pathogenesis and promotes tumor growth, migration/invasion, and angiogenesis, hence conferring clinical aggressiveness and representing a novel therapeutic target of DZNep therapy.
    Date: 2014-02
    Relation: Modern Pathology. 2014 Feb;27(Suppl. 2):22A.
    Link to: http://dx.doi.org/10.1038/modpathol.2014.6
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0893-3952&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000331502200075
    Appears in Collections:[Others] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000331502200075.pdf131KbAdobe PDF598View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback